We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
(-30%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
266.32%
Top 10 Holdings %
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
Baxter International
BAX
|
+$3.81M |
| 3 |
Akebia Therapeutics
AKBA
|
+$2.87M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$2.46M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$1.81M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
+$8.82M |
| 2 |
CELG
Celgene Corp
CELG
|
+$6.57M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$6.35M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$5.44M |
| 5 |
Viatris
VTRS
|
+$2.57M |
Sector Composition
| 1 | Healthcare | 48.43% |
| 2 | Technology | 4.06% |
| 3 | Consumer Discretionary | 2.5% |
| 4 | Consumer Staples | 1.74% |
| 5 | Materials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Insperity
NSP
$1.89B
| – | – |
-38,708
| Closed | -$932K |
|
|
327
PUT
Insperity
NSP
$1.89B
| – | – |
-6,200
| Closed | -$38K |
|
328
CALL
NVIDIA
NVDA
$5.02T
| – | – |
-960,000
| Closed | -$54K |
|
|
329
NVIDIA
NVDA
$5.02T
| – | – |
-224,000
| Closed | -$185K |
|
|
330
PUT
NVIDIA
NVDA
$5.02T
| – | – |
-988,000
| Closed | -$35K |
|
331
Opko Health
OPK
$899M
| – | – |
-27,266
| Closed | -$274K |
|
|
332
PUT
Opko Health
OPK
$899M
| – | – |
-50,000
| Closed | -$548K |
|
333
CALL
Pacira BioSciences
PCRX
$1.01B
| – | – |
-54,400
| Closed | -$971K |
|
|
334
Pacira BioSciences
PCRX
$1.01B
| – | – |
-3,500
| Closed | -$269K |
|
|
335
PUT
Pacira BioSciences
PCRX
$1.01B
| – | – |
-2,000
| Closed | -$2K |
|
336
Precigen
PGEN
$1.76B
| – | – |
-24,265
| Closed | -$764K |
|
337
PUT
PTC Therapeutics
PTCT
$6.51B
| – | – |
-5,000
| Closed | -$162K |
|
338
CALL
Qualcomm
QCOM
$180B
| – | – |
-71,000
| Closed | -$195K |
|
|
339
Qualcomm
QCOM
$180B
| – | – |
-9,200
| Closed | -$460K |
|
|
340
PUT
Qualcomm
QCOM
$180B
| – | – |
-67,200
| Closed | -$122K |
|
341
Synchrony
SYF
$25B
| – | – |
-36,033
| Closed | -$1.1M |
|
|
342
PUT
Synchrony
SYF
$25B
| – | – |
-20,000
| Closed | -$193K |
|
343
AT&T
T
$153B
| – | – |
-39,581
| Closed | -$1.1M |
|
344
CALL
United Therapeutics
UTHR
$22.5B
| – | – |
-15,200
| Closed | -$90K |
|
|
345
United Therapeutics
UTHR
$22.5B
| – | – |
-13,267
| Closed | -$2.08M |
|
|
346
PUT
United Therapeutics
UTHR
$22.5B
| – | – |
-50,000
| Closed | -$53K |
|
|
347
Viatris
VTRS
$20.2B
| – | – |
-47,500
| Closed | -$2.57M |
|
|
348
PUT
Viatris
VTRS
$20.2B
| – | – |
-47,500
| Closed | -$740K |
|
349
Verizon
VZ
$183B
| – | – |
-5,709
| Closed | -$286K |
|
350
CALL
Yum! Brands
YUM
$41.9B
| – | – |
-153,427
| Closed | -$169K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2016 Portfolio in Review
As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.
- FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
- FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
- FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
- FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
- FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
- FT Options opened 183 new positions and closed 99 in Q1 2016.
- FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.
Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.